1-2 of 2
Yufei Chen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47

Matthew R. Levengood, Christopher M. Carosino, Xinqun Zhang, Sasha Lucas, David J. Ortiz, Lori Westendorf, Alice P. Chin, Arlan D. Martin, Abbie Wong, Shawna M. Hengel, Hao Sun, Weiping Zeng, Roma Yumul, Melissa M.C. Dominguez, Yufei Chen, Janet H. Zheng, Courtney A.B. Karlsson, Vivian H. Trang, Peter D. Senter, Shyra J. Gardai
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther OF1–OF14.
https://doi.org/10.1158/1535-7163.MCT-24-0371
Published: 22 November 2024
View article titled, Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Open the PDF for Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47 in another window
Includes: Supplementary data
Journal Articles

Abstract C132: SGN-35T: A novel CD30-directed antibody-drug conjugate for the treatment of lymphomas

Kevin J Hamblett, Steven Jin, Roma Yumul, Yufei Chen, John Kwon, Jessica Simmons, Clark Henderson, Hao Sun, Jason P Schrum, Andrea R Lim, Noah A Bindman, Melissa Conerly, Astrid Clarke
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C132.
https://doi.org/10.1158/1535-7163.TARG-23-C132
Published: 01 December 2023
View article titled, Abstract C132: SGN-35T: A novel CD30-directed antibody-drug conjugate for the treatment of lymphomas